Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Fiera Capital Corp

Fiera Capital Corp lessened its stake in Inari Medical, Inc. (NASDAQ:NARI) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 563,567 shares of the company’s stock after selling 19,821 shares during the quarter. Fiera Capital Corp owned about 0.96% of Inari Medical worth $23,242,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Asset Management L.P. grew its position in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after acquiring an additional 786,691 shares during the period. Armistice Capital LLC raised its holdings in Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after buying an additional 786,501 shares during the period. Vanguard Group Inc. lifted its position in Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after buying an additional 561,562 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Inari Medical by 1,219.9% during the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after buying an additional 364,983 shares during the period. Finally, First Light Asset Management LLC raised its stake in shares of Inari Medical by 120.8% in the 2nd quarter. First Light Asset Management LLC now owns 472,384 shares of the company’s stock valued at $22,745,000 after acquiring an additional 258,444 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 131,000 shares of company stock worth $6,161,340. 10.60% of the stock is currently owned by company insiders.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $51.39 on Friday. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13. The company’s fifty day moving average is $44.43 and its two-hundred day moving average is $46.49. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -38.07 and a beta of 0.96.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Stifel Nicolaus initiated coverage on Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target for the company. Robert W. Baird increased their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Wells Fargo & Company reduced their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Finally, Canaccord Genuity Group boosted their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.